Brought to you by 
BeyondSpring raises $15.25mm through Series B round
08 Dec 2016
Executive Summary
BeyondSpring Inc. raised $15.25mm through its Series B round. Investors included Epiphron Capital Fund, Broad Resources Value and Growth, Suzhou Broad Resources Ling Long Private Equity, Beijing Huarong Sangel Venture Capital, and individual investors, including the president of a division of Fosun. BeyondSpring is developing cancer therapies, and has its lead candidate plinabulin in Phase II and III trials for non-small cell lung cancer and prevention of chemotherapy-induced neutropenia.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BeyondSpring raises $15.25mm through Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice